Life After Fontan: How HeartWorks Is Creating New Hope for Single-Ventricle Patients

woman with hands placed over her heart

For babies born with only one functional heart pump, a condition known as single ventricle physiology, the journey through childhood often involves multiple lifesaving surgeries. The Fontan procedure is usually the final major surgery.

The Fontan creates a unique circulation system: instead of two pumping chambers, one for the lungs and one for the body, there is only one. Blood returning from the body, low in oxygen (“blue blood”), flows passively to the lungs without the help of a pump. Once the lungs add oxygen, the blood (“red blood”) returns to the single working ventricle, which pumps it out to the rest of the body.

This circulation gives children the chance to grow, learn, and thrive. But as they reach adulthood, the unique system created by the Fontan procedure can bring challenges, limited exercise tolerance, liver complications, and increased risk of heart failure. Historically, there have been few options for patients facing complications after Fontan surgery.

HeartWorks and the Future of Single Ventricle Research

HeartWorks is at the forefront of single ventricle research, pioneering treatments and technologies to improve life after Fontan. Their mission is to transform what’s possible for patients born with one functional heart pump, moving beyond survival to long-term health, quality of life, and new horizons of care.

Some of the most promising areas include:

  • Autologous Stem Cell Clinical Trials: HeartWorks supports cutting-edge trials using a patient’s own stem cells to strengthen the single ventricle heart muscle and improve its ability to pump blood effectively. This regenerative approach could help delay or even prevent heart failure in single ventricle patients. Visit our clinical trials page for more information.
  • Advanced Therapies for Single Ventricle Hearts: From innovative medications to novel devices, researchers are exploring treatments designed specifically for the unique Fontan circulation system, reducing strain on the heart and boosting oxygen delivery throughout the body.
  • Next-Generation Mechanical Heart Support: HeartWorks is funding research into mechanical heart pumps tailored to patients with single ventricle physiology, offering more options when heart function declines.
  • Comprehensive Data: The Co-op at HeartWorks is a first-of-its-kind data cooperative that makes it simple for CHD families to securely share their stories and medical information to drive real change in research and care.

More Options, More Hope

The era of limited options after Fontan is changing. Through autologous stem cell clinical trials and groundbreaking single ventricle research, HeartWorks is building a future where children born with one functional heart pump can live longer, healthier lives, with more treatments, better outcomes, and greater hope than ever before.

For more information, contact hello@webuildhearts.org or schedule a virtual lab tour.

Share the Post:

Related Posts

Emma Hofmeister, Onboarding Specialist for The Co-op at HeartWorks

Supporting CHD Families Through Connection: Meet Emma Hofmeister, Onboarding Specialist for The Co-op @ HeartWorks 

Meet Emma Hofmeister, the Onboarding Specialist for The Co-op @ HeartWorks. Emma transitioned into her current role after beginning her career as a Lab Technician. For the past year and a half, her work has been multifaceted, blending community outreach with direct family support. A typical day for Emma might include presenting at a webinar to promote The Co-op, meticulously tracking records to support families, or connecting with members to answer questions about the enrollment process. She is also involved in the creation of the upcoming second Co-op journal. For Emma, the most inspiring moments are the conversations she has with heart families, whose trust and hope she says are the driving force behind the team’s mission.

Read More
HeartWorks World Headquarters in Eau Claire, WI

HeartWorks World Headquarters  |   A New Home Driving Hope for CHD Families

We’re thrilled to share an exciting milestone: the new HeartWorks World Headquarters in Eau Claire, WI! This state-of-the-art research and manufacturing facility is the heart of our mission, bringing all our teams under one roof to accelerate our life-changing work for congenital heart disease (CHD) families.

The new headquarters will dramatically increase our clinical manufacturing capacity, allowing us to produce up to 100 induced pluripotent stem cell lines per year – a significant leap from our previous capacity of 12. This expansion is critical, as it means more clinical trials, new personalized treatments, and, most importantly, more hope for those affected by CHD.

Read More

Send A Message

This field is for validation purposes and should be left unchanged.
Name(Required)
Please let us know what's on your mind. Have a question for us? Ask away.